Developer docs
API playgroundTry for free, no card

Search company profiles

Bioserve

Full company profile

uuid00hhxty

Namestring
Bioserve
Legal namestring
Bioserve Biotechnologies (India) Pvt. Ltd.
Websiteurl
bioserve.in
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Bioserve Biotechnologies (India) Pvt. Ltd. is a Hyderabad-based molecular biology services and products company operating as the wholly-owned India subsidiary of REPROCELL Inc. (Tokyo Stock Exchange: 4978), Japan's first publicly listed iPSC company. Founded in 1994 and headquartered in Nacharam, Hyderabad, the company serves Indian pharmaceutical and biotechnology companies (Syngene, Lupin, Dr. Reddy's, Biological E, Aurobindo, Aurigene, Alembic, Zydus), academic and research institutions (IIT Madras, IIT Bombay, IARI), and healthcare providers (AIIMS). Bioserve's core capabilities span custom oligonucleotide synthesis (including proprietary Long Mer® oligos up to 150 bases and NGS Grade® oligos), the PreciONC clinical diagnostics suite (cancer panels covering 409 tumor suppressor/oncogenes with TMB/MSI testing, BRCA extended, hereditary cancers, lung RNA fusion, leukemia, and colorectal panels), molecular services (Sanger sequencing on ABI 3730 platforms, NGS on Illumina/PacBio/Oxford Nanopore, microbial ID and DNA barcoding), and stem cell products distributed from REPROCELL's portfolio (StemRNA™ reprogramming kits, iPSCs, MSCs, Alvetex 3D culture, ABLE Biott bioreactors, Qkine growth factors).

The company makes money through project-based and unit-based fees across five streams: oligonucleotide synthesis (one-time synthesis fees, 10-1000 nmole scale tiers), peptide synthesis (catalog and custom including GMP-grade APIs via HLB PEP), clinical diagnostics (precision oncology professional services), molecular services (sequencing and barcoding per-sample pricing), and stem cell product distribution (REPROCELL/Qkine/HLB PEP catalogs). Pricing is quote-based and not publicly disclosed; services are sold via direct sales, downloadable order forms, inside sales contacts (e.g., Oligo Synthesis, CRO, Sanger order forms), and event-driven lead generation at industry conferences. Bioserve holds ISO 9001:2015 and Clinical Establishment certifications, operates GMP procedures for peptide and iPSC manufacturing, and is currently expanding through new clinical product launches (NeoSight neoantigen detection, launched August 2025) and distribution partnerships.

Short descriptiontext

Bioserve is a Hyderabad-based molecular biology services company and India subsidiary of REPROCELL Inc. offering custom oligonucleotide synthesis, NGS/Sanger sequencing, the PreciONC clinical oncology diagnostics suite, and stem cell products to Indian pharmaceutical companies, academic institutions, and healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oligonucleotide synthesis, clinical diagnostics, next-generation sequencing, stem cell reagents, molecular biology services
Industry3 codes
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
Product category
Genomics & Molecular Biology Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Oligonucleotide Synthesis Services
TypeOne Time License
Description

Custom DNA oligo synthesis services with various scales (10-1000 nmole), purification options, and modifications including dyes, quenchers, and labeled bases. Revenue generated from one-time synthesis fees with optional premium purification tiers.

bioserve.in
2Peptide Synthesis Services
TypeOne Time License
Description

Custom peptide synthesis including catalog peptides (1000+), custom peptides (long-chain, modified, bulk-scale), and GMP-grade peptide APIs. Manufactured under GMP procedures with full traceability.

bioserve.in
3Clinical Diagnostics Services
TypeProfessional Services
Description

Precision oncology services including cancer panels (BRCA 1/2, Comprehensive Cancer Panel, Hereditary Cancers Panel), MSI testing, and biomarker testing for clinical diagnostics

bioserve.in
4Molecular Services
TypeProfessional Services
Description

Sanger sequencing (3-4 business days turnaround), Next-Generation Sequencing (DNA and RNA), microbial identification, and DNA barcoding services

bioserve.in
5Stem Cell Products
TypeHardware Sales
Description

Stem cell reagents, iPSCs, growth factors, cytokines, 3D cell culture products, and labware distributed through REPROCELL brand portfolio

bioserve.in
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details3 tiers
1Oligo Synthesis - Scale-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Oligos synthesized on 10, 20, 25, 50, 100, 200 and 1000 nmole scales. Prices vary by scale and purification level. Desalted and lyophilized products as standard.

bioserve.in
2Sanger Sequencing - Sample-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices start at competitive rates with discounts for bulk orders. Turnaround time 2-3 business days. Raw sequence files provided with optional analysis services.

bioserve.in
3Qkine Growth Factors - Catalog products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Over 1000 catalog peptides available at competitive prices. High purity (>95% HPLC tested) with TFA counter ions as standard.

bioserve.in
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1PreciONC
Description

Precision oncology services including cancer genetic testing panels (BRCA, comprehensive cancer panel, inherited cancers panel, colorectal cancer panel, leukemia testing, MSI testing, lung RNA fusion panel)

bioserve.in
+4 more records
Core offering1 text field

Bioserve is a molecular biology services and genomics company offering custom oligonucleotide synthesis (DNA oligos up to 150 bases), clinical diagnostics for oncology (BRCA, MSI, comprehensive cancer panels, lung RNA fusion panels), molecular services (Sanger sequencing, NGS, DNA barcoding, microbial identification, cell line authentication), neoantigen discovery for cancer immunotherapy, and stem cell research products including iPSCs, MSCs, growth factors, cytokines, and 3D cell culture systems. The company distributes REPROCELL group products, HLB PEP peptides, and Qkine growth factors to pharmaceutical, academic, and clinical customers in India.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100+ completed projects
+3 more records
Product overview1 text field

Bioserve is a comprehensive molecular biology services and products company offering oligonucleotide synthesis, clinical diagnostics, and stem cell research reagents. The core portfolio includes Oligosynthesis Services (custom DNA oligonucleotides including Long Mer DNA oligos up to 150 bases, Modified DNA oligos, NGS Grade oligos), the PreciONC Oncology clinical diagnostics suite (Integrated Tumor Panel+, MSI Testing, Lung RNA Fusion Panel, BRCA Extended Panel, Comprehensive Cancer Panel, Hereditary Cancers Panel, Colorectal Cancer Panel, Leukemia Panels), and Stem Cell Products (StemRNA reprogramming kits, iPSCs, MSCs, growth factors/cytokines from Qkine, 3D cell culture systems like Alvetex, bioreactors, and peptides from HLB PEP). The company also provides molecular services including Sanger Sequencing, Next-Generation Sequencing (Illumina, PacBio, Oxford Nanopore), DNA Barcoding, Microbial Identification, and Human Cell Line Authentication. Services are supported by ISO 9001:2015 certification and REPROCELL group partnership.

Product and service16 records
1Oligonucleotide Synthesis Services
CategoryOligonucleotide Synthesis
Description

Custom DNA oligonucleotide synthesis services including Long Mer® DNA oligos (up to 150 bases), NGS Grade® oligos, modified DNA oligos with fluorescent labels and quenchers, and universal primers. Synthesized at scales from 10 to 1000 nmole with various purification options for pharmaceutical, biotech, and academic researchers.

2PreciONC Oncology Clinical Diagnostics
CategoryClinical Diagnostics
Description

Integrated molecular diagnostic suite for oncology covering hereditary risk assessment, differential diagnosis, prognosis, targeted treatment selection, therapy monitoring, and disease surveillance through multiple cancer panels.

3NeoSight Neoantigen Detection Service
CategoryClinical Diagnostics / Immunotherapy
Description

End-to-end neoantigen discovery platform combining Whole Exome Sequencing (WES), RNA Sequencing, and computational MHC-binding prediction algorithms to identify tumor-specific neoantigens for personalized cancer immunotherapy, with annotated VCF/TSV variant files, prioritized neoantigen lists, HLA typing, and TMB reports.

4Human Cell Line Authentication Service
5Sanger Sequencing Services
6Next-Generation Sequencing Services
7DNA Barcoding Services
8Microbial Identification Service
9StemRNA 3rd Gen Reprogramming Kit
10Induced Pluripotent Stem Cells (iPSCs)
11Qkine Growth Factors and Cytokines
12HLB PEP Peptide Solutions
CategoryPeptide Products
Description

Peptide products including catalog peptides (>1000 hormones, neuropeptides, antibiotic peptides), custom peptide synthesis (long-chain, modified, bulk-scale), generic peptide APIs (Desmopressin, Leuprorelin, Ganirelix), and GMP-grade peptides from Korea's first MFDS-approved peptide facility.

13PreciONC Hereditary Cancers Panel
14PreciONC BRCA Extended Panel
15PreciONC MSI Testing
16PreciONC Lung RNA Fusion Panel
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

Joint GMP certification achieved with Histocell for manufacturing clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs. Spanish AEMPS (under EMA oversight) granted GMP certification.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-08-13
Description

REPROCELL Europe collaborated with Durham University researchers to develop iPSC-derived full-thickness human skin model. Breakthrough published in Cells journal (14(14):1044, 2025).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-11
Description

Exclusive distribution agreement for peptide products in Indian market. HLB PEP is Korea's first GMP-certified peptide CMO, providing catalog peptides, custom synthesis, and GMP-grade APIs. Creates synergies with Bioserve's existing oligosynthesis operations.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

REPROCELL holds exclusive commercialization license for Stemchymal® (stem cell therapy) in Japan for treatment of Spinocerebellar Ataxia (SCA). Phase II clinical trial results announced April 2025 showing positive outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-10
Description

Global distributorship partnership for high-quality bioactive proteins including growth factors and cytokines for stem cell culture. Qkine's animal-origin-free manufacturing combined with REPROCELL's stem cell expertise and global network enables distribution to stem cell scientists worldwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent company and strategic partner. Bioserve is the India operations of Japan's first iPSC company. REPROCELL provides access to StemRNA™ technology, global product portfolio, and operates subsidiaries in Americas (REPROCELL USA) and Europe (REPROCELL Europe).

Strategic tierMinorTypeOthers
Description

Global product partner for research products distributed through Bioserve in India

Strategic tierMinorTypeOthers
Description

Global product partner for oligonucleotide synthesis reagents and products distributed through Bioserve in India

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based genomics and clinical diagnostics company offering NGS-based oncology panels, hereditary cancer testing, and molecular diagnostics — directly comparable to Bioserve's PreciONC oncology and clinical diagnostics services.

TypeBroad incumbent
Description

Global market leader in custom oligonucleotide synthesis (now part of Danaher) with industry-leading product depth, NGS oligos, and molecular tools — the dominant incumbent competitor to Bioserve's core oligo synthesis business.

TypeDirect peer
Description

India-based clinical genomics and bioinformatics company providing cancer panel testing, hereditary cancer diagnostics, and molecular services to hospitals and pharma — directly overlapping with Bioserve's clinical diagnostics and molecular services portfolio.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive custom oligonucleotide synthesis, gene synthesis, peptide synthesis, and protein services. A major incumbent serving Indian pharma and academic customers with broader catalog and global scale than Bioserve.

TypeRegional player
Description

Korea-based genomics services company providing Sanger sequencing, NGS, and oligo synthesis across Asia. Comparable service menu to Bioserve but serves Asian customers from Korean operations rather than India.

TypeBroad incumbent
Description

Global genomics services provider offering custom oligos, Sanger and NGS sequencing, and genotyping — directly competing with Bioserve's molecular services and oligo synthesis but with much broader geographic and catalog reach.

TypeEmerging player
Description

India-based precision oncology company offering NGS-based cancer panels and molecular diagnostics — emerging competitor in the same Indian clinical genomics market as Bioserve's PreciONC oncology suite.

TypeDirect peer
Description

India-based genomics services company offering NGS, Sanger sequencing, and molecular biology services to research and pharma customers — directly overlapping with Bioserve's molecular services offering within India.

TypeDirect peer
Description

India-based genomics and bioinformatics CRO providing microarray, NGS, gene expression, and bioIT services to global pharma and research customers — overlapping with Bioserve's molecular biology and bioinformatics service lines.

TypeRegional player
Description

Korea-based molecular biology company offering oligonucleotide synthesis, NGS services, and molecular diagnostics — comparable in service menu to Bioserve and connected via the HLB PEP/Asian biotech distribution ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioserve

Genomics & Molecular Biology Servicesbioserve.in

Bioserve is a Hyderabad-based molecular biology services company and India subsidiary of REPROCELL Inc. offering custom oligonucleotide synthesis, NGS/Sanger sequencing, the PreciONC clinical oncology diagnostics suite, and stem cell products to Indian pharmaceutical companies, academic institutions, and healthcare providers.

What Bioserve does

Bioserve Biotechnologies (India) Pvt. Ltd. is a Hyderabad-based molecular biology services and products company operating as the wholly-owned India subsidiary of REPROCELL Inc. (Tokyo Stock Exchange: 4978), Japan's first publicly listed iPSC company. Founded in 1994 and headquartered in Nacharam, Hyderabad, the company serves Indian pharmaceutical and biotechnology companies (Syngene, Lupin, Dr. Reddy's, Biological E, Aurobindo, Aurigene, Alembic, Zydus), academic and research institutions (IIT Madras, IIT Bombay, IARI), and healthcare providers (AIIMS). Bioserve's core capabilities span custom oligonucleotide synthesis (including proprietary Long Mer® oligos up to 150 bases and NGS Grade® oligos), the PreciONC clinical diagnostics suite (cancer panels covering 409 tumor suppressor/oncogenes with TMB/MSI testing, BRCA extended, hereditary cancers, lung RNA fusion, leukemia, and colorectal panels), molecular services (Sanger sequencing on ABI 3730 platforms, NGS on Illumina/PacBio/Oxford Nanopore, microbial ID and DNA barcoding), and stem cell products distributed from REPROCELL's portfolio (StemRNA™ reprogramming kits, iPSCs, MSCs, Alvetex 3D culture, ABLE Biott bioreactors, Qkine growth factors).

The company makes money through project-based and unit-based fees across five streams: oligonucleotide synthesis (one-time synthesis fees, 10-1000 nmole scale tiers), peptide synthesis (catalog and custom including GMP-grade APIs via HLB PEP), clinical diagnostics (precision oncology professional services), molecular services (sequencing and barcoding per-sample pricing), and stem cell product distribution (REPROCELL/Qkine/HLB PEP catalogs). Pricing is quote-based and not publicly disclosed; services are sold via direct sales, downloadable order forms, inside sales contacts (e.g., Oligo Synthesis, CRO, Sanger order forms), and event-driven lead generation at industry conferences. Bioserve holds ISO 9001:2015 and Clinical Establishment certifications, operates GMP procedures for peptide and iPSC manufacturing, and is currently expanding through new clinical product launches (NeoSight neoantigen detection, launched August 2025) and distribution partnerships.

Bioserve firmographics

Firmographics
Name
Bioserve
Legal name
Bioserve Biotechnologies (India) Pvt. Ltd.
Website
https://bioserve.in
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
51–100 employees
Short description
Bioserve is a Hyderabad-based molecular biology services company and India subsidiary of REPROCELL Inc. offering custom oligonucleotide synthesis, NGS/Sanger sequencing, the PreciONC clinical oncology diagnostics suite, and stem cell products to Indian pharmaceutical companies, academic institutions, and healthcare providers.
Ownership category
akta.pro rank

Bioserve industry classification

Industry
Product category
Genomics & Molecular Biology Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Oligonucleotide synthesis
  • Clinical diagnostics
  • Next-generation sequencing
  • Stem cell reagents
  • Molecular biology services

Where Bioserve is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Bioserve business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Oligonucleotide Synthesis Services: Custom DNA oligo synthesis services with various scales (10-1000 nmole), purification options, and modifications including dyes, quenchers, and labeled bases. Revenue generated from one-time synthesis fees with optional premium purification tiers.
  2. Peptide Synthesis Services: Custom peptide synthesis including catalog peptides (1000+), custom peptides (long-chain, modified, bulk-scale), and GMP-grade peptide APIs. Manufactured under GMP procedures with full traceability.
  3. Clinical Diagnostics Services: Precision oncology services including cancer panels (BRCA 1/2, Comprehensive Cancer Panel, Hereditary Cancers Panel), MSI testing, and biomarker testing for clinical diagnostics
  4. Molecular Services: Sanger sequencing (3-4 business days turnaround), Next-Generation Sequencing (DNA and RNA), microbial identification, and DNA barcoding services
  5. Stem Cell Products: Stem cell reagents, iPSCs, growth factors, cytokines, 3D cell culture products, and labware distributed through REPROCELL brand portfolio

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOligo Synthesis - Scale-based pricing
Unit PricingPay-as-you-goSanger Sequencing - Sample-based pricing
Unit PricingPay-as-you-goQkine Growth Factors - Catalog products

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Bioserve product offering

Product offering

Core offering

Bioserve is a molecular biology services and genomics company offering custom oligonucleotide synthesis (DNA oligos up to 150 bases), clinical diagnostics for oncology (BRCA, MSI, comprehensive cancer panels, lung RNA fusion panels), molecular services (Sanger sequencing, NGS, DNA barcoding, microbial identification, cell line authentication), neoantigen discovery for cancer immunotherapy, and stem cell research products including iPSCs, MSCs, growth factors, cytokines, and 3D cell culture systems. The company distributes REPROCELL group products, HLB PEP peptides, and Qkine growth factors to pharmaceutical, academic, and clinical customers in India.

Product overview

Bioserve is a comprehensive molecular biology services and products company offering oligonucleotide synthesis, clinical diagnostics, and stem cell research reagents. The core portfolio includes Oligosynthesis Services (custom DNA oligonucleotides including Long Mer DNA oligos up to 150 bases, Modified DNA oligos, NGS Grade oligos), the PreciONC Oncology clinical diagnostics suite (Integrated Tumor Panel+, MSI Testing, Lung RNA Fusion Panel, BRCA Extended Panel, Comprehensive Cancer Panel, Hereditary Cancers Panel, Colorectal Cancer Panel, Leukemia Panels), and Stem Cell Products (StemRNA reprogramming kits, iPSCs, MSCs, growth factors/cytokines from Qkine, 3D cell culture systems like Alvetex, bioreactors, and peptides from HLB PEP). The company also provides molecular services including Sanger Sequencing, Next-Generation Sequencing (Illumina, PacBio, Oxford Nanopore), DNA Barcoding, Microbial Identification, and Human Cell Line Authentication. Services are supported by ISO 9001:2015 certification and REPROCELL group partnership.

Differentiator

Problem solved

Functional benefit

Brands

  • PreciONC: Precision oncology services including cancer genetic testing panels (BRCA, comprehensive cancer panel, inherited cancers panel, colorectal cancer panel, leukemia testing, MSI testing, lung RNA fusion panel)
  • REPROCELL Group Products
  • Long Mer
  • NGS Grade
  • StemRNA

Products and services

  • Oligonucleotide Synthesis Services Custom DNA oligonucleotide synthesis services including Long Mer® DNA oligos (up to 150 bases), NGS Grade® oligos, modified DNA oligos with fluorescent labels and quenchers, and universal primers. Synthesized at scales from 10 to 1000 nmole with various purification options for pharmaceutical, biotech, and academic researchers.
  • PreciONC Oncology Clinical Diagnostics Integrated molecular diagnostic suite for oncology covering hereditary risk assessment, differential diagnosis, prognosis, targeted treatment selection, therapy monitoring, and disease surveillance through multiple cancer panels.
  • NeoSight Neoantigen Detection Service End-to-end neoantigen discovery platform combining Whole Exome Sequencing (WES), RNA Sequencing, and computational MHC-binding prediction algorithms to identify tumor-specific neoantigens for personalized cancer immunotherapy, with annotated VCF/TSV variant files, prioritized neoantigen lists, HLA typing, and TMB reports.
  • Human Cell Line Authentication Service
  • Sanger Sequencing Services
  • Next-Generation Sequencing Services
  • DNA Barcoding Services
  • Microbial Identification Service
  • StemRNA 3rd Gen Reprogramming Kit
  • Induced Pluripotent Stem Cells (iPSCs)
  • Qkine Growth Factors and Cytokines
  • HLB PEP Peptide Solutions Peptide products including catalog peptides (>1000 hormones, neuropeptides, antibiotic peptides), custom peptide synthesis (long-chain, modified, bulk-scale), generic peptide APIs (Desmopressin, Leuprorelin, Ganirelix), and GMP-grade peptides from Korea's first MFDS-approved peptide facility.
  • PreciONC Hereditary Cancers Panel
  • PreciONC BRCA Extended Panel
  • PreciONC MSI Testing
  • PreciONC Lung RNA Fusion Panel

Quantifiable outcome

  • 100+ completed projects
  • +3 more outcomes

Companies that use Bioserve

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Bioserve technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Bioserve partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic, core and minor.

  • Histocell S.L.strategicStrategic or Co-development Partner · 20 October 2025Joint GMP certification achieved with Histocell for manufacturing clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs. Spanish AEMPS (under EMA oversight) granted GMP certification.
  • Durham UniversitystrategicStrategic or Co-development Partner · 13 August 2025REPROCELL Europe collaborated with Durham University researchers to develop iPSC-derived full-thickness human skin model. Breakthrough published in Cells journal (14(14):1044, 2025).
  • HLB PEP Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 11 August 2025Exclusive distribution agreement for peptide products in Indian market. HLB PEP is Korea's first GMP-certified peptide CMO, providing catalog peptides, custom synthesis, and GMP-grade APIs. Creates synergies with Bioserve's existing oligosynthesis operations.
  • Steminent Biotherapeutics Inc.strategicStrategic or Co-development Partner · 25 April 2025REPROCELL holds exclusive commercialization license for Stemchymal® (stem cell therapy) in Japan for treatment of Spinocerebellar Ataxia (SCA). Phase II clinical trial results announced April 2025 showing positive outcomes.
  • Qkine Ltd.coreStrategic or Co-development Partner · 10 January 2025Global distributorship partnership for high-quality bioactive proteins including growth factors and cytokines for stem cell culture. Qkine's animal-origin-free manufacturing combined with REPROCELL's stem cell expertise and global network enables distribution to stem cell scientists worldwide.
  • REPROCELL Inc.coreStrategic or Co-development PartnerParent company and strategic partner. Bioserve is the India operations of Japan's first iPSC company. REPROCELL provides access to StemRNA™ technology, global product portfolio, and operates subsidiaries in Americas (REPROCELL USA) and Europe (REPROCELL Europe).
  • Axion BiosystemsminorOthersGlobal product partner for research products distributed through Bioserve in India
  • Glen ResearchminorOthersGlobal product partner for oligonucleotide synthesis reagents and products distributed through Bioserve in India

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Bioserve competitors and assessment

Company assessment

Direct peers

  • MedGenome: India-based genomics and clinical diagnostics company offering NGS-based oncology panels, hereditary cancer testing, and molecular diagnostics — directly comparable to Bioserve's PreciONC oncology and clinical diagnostics services.
  • Strand Life Sciences: India-based clinical genomics and bioinformatics company providing cancer panel testing, hereditary cancer diagnostics, and molecular services to hospitals and pharma — directly overlapping with Bioserve's clinical diagnostics and molecular services portfolio.
  • SciGenom Labs: India-based genomics services company offering NGS, Sanger sequencing, and molecular biology services to research and pharma customers — directly overlapping with Bioserve's molecular services offering within India.
  • Ocimum Biosolutions: India-based genomics and bioinformatics CRO providing microarray, NGS, gene expression, and bioIT services to global pharma and research customers — overlapping with Bioserve's molecular biology and bioinformatics service lines.

Broad incumbents

  • Integrated DNA Technologies (IDT): Global market leader in custom oligonucleotide synthesis (now part of Danaher) with industry-leading product depth, NGS oligos, and molecular tools — the dominant incumbent competitor to Bioserve's core oligo synthesis business.
  • GenScript: Global CRO/CDMO with extensive custom oligonucleotide synthesis, gene synthesis, peptide synthesis, and protein services. A major incumbent serving Indian pharma and academic customers with broader catalog and global scale than Bioserve.
  • Eurofins Genomics: Global genomics services provider offering custom oligos, Sanger and NGS sequencing, and genotyping — directly competing with Bioserve's molecular services and oligo synthesis but with much broader geographic and catalog reach.

Regional players

  • Macrogen: Korea-based genomics services company providing Sanger sequencing, NGS, and oligo synthesis across Asia. Comparable service menu to Bioserve but serves Asian customers from Korean operations rather than India.
  • Bioneer: Korea-based molecular biology company offering oligonucleotide synthesis, NGS services, and molecular diagnostics — comparable in service menu to Bioserve and connected via the HLB PEP/Asian biotech distribution ecosystem.

Emerging players

  • 4baseCare: India-based precision oncology company offering NGS-based cancer panels and molecular diagnostics — emerging competitor in the same Indian clinical genomics market as Bioserve's PreciONC oncology suite.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Bioserve social profiles

Digital presence

Bioserve compliance and trust

Trust signal

Compliance2 records

Bioserve financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioserve leadership team

Management profile

Number of profiles

Profiles4 records

Bioserve funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioserve M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioserve

What does Bioserve do?

Bioserve is a molecular biology services and genomics company offering custom oligonucleotide synthesis (DNA oligos up to 150 bases), clinical diagnostics for oncology (BRCA, MSI, comprehensive cancer panels, lung RNA fusion panels), molecular services (Sanger sequencing, NGS, DNA barcoding, microbial identification, cell line authentication), neoantigen discovery for cancer immunotherapy, and stem cell research products including iPSCs, MSCs, growth factors, cytokines, and 3D cell culture systems. The company distributes REPROCELL group products, HLB PEP peptides, and Qkine growth factors to pharmaceutical, academic, and clinical customers in India.

Is Bioserve a public or private company?

Bioserve is a private company. It is classified as corporate owned and is currently operating.

When was Bioserve founded?

Bioserve was founded in 1994. It employs 51 to 100 people.

Where is Bioserve based?

Bioserve is headquartered in Hyderabad, India, in the Asia region.

How does Bioserve make money?

Five revenue lines are on record. Oligonucleotide Synthesis Services are the primary driver. The others are peptide Synthesis Services, clinical Diagnostics Services, molecular Services and stem Cell Products.

Who are Bioserve's main competitors?

Direct peers on record are MedGenome, Strand Life Sciences, SciGenom Labs and Ocimum Biosolutions. Broad incumbents are Integrated DNA Technologies (IDT), GenScript and Eurofins Genomics. Regional players are Macrogen and Bioneer. 4baseCare is listed as an emerging player.

Does Bioserve have an API?

No public API is recorded for Bioserve.

What industry is Bioserve in?

Bioserve's product category is Genomics & Molecular Biology Services. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales